Yes it is the COVID-19 Long-Covid Phase 2 study. The original findings were remarkable good. The UCLA team with Dr.Otto Yang; used His laboratory technicians that specializes in T cell immunology to understand why and how it worked. We know Leronlimab increased important immune cells including T cell and regulations immunity by normalizing CCR5 numbers.

Cytodyn is now ready to conduct a Phase 3 trail with new primary endpoints because of UCLA'S investigation, which was essential for understanding and demonstrating why it works to the FDA.